JP6063472B2 - 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 - Google Patents

骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 Download PDF

Info

Publication number
JP6063472B2
JP6063472B2 JP2014540200A JP2014540200A JP6063472B2 JP 6063472 B2 JP6063472 B2 JP 6063472B2 JP 2014540200 A JP2014540200 A JP 2014540200A JP 2014540200 A JP2014540200 A JP 2014540200A JP 6063472 B2 JP6063472 B2 JP 6063472B2
Authority
JP
Japan
Prior art keywords
compound
cells
catenin
tbl1
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014540200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534229A5 (enExample
JP2014534229A (ja
Inventor
カピル エヌ． バラ
カピル エヌ． バラ
スティーブン ホリガン
スティーブン ホリガン
Original Assignee
ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー
ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー, ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー filed Critical ベータ キャット ファーマシューティカルズ リミテッド ライアビリティ カンパニー
Publication of JP2014534229A publication Critical patent/JP2014534229A/ja
Publication of JP2014534229A5 publication Critical patent/JP2014534229A5/ja
Application granted granted Critical
Publication of JP6063472B2 publication Critical patent/JP6063472B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014540200A 2011-11-06 2012-11-06 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 Active JP6063472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
US61/556,245 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (3)

Publication Number Publication Date
JP2014534229A JP2014534229A (ja) 2014-12-18
JP2014534229A5 JP2014534229A5 (enExample) 2015-02-05
JP6063472B2 true JP6063472B2 (ja) 2017-01-18

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540200A Active JP6063472B2 (ja) 2011-11-06 2012-11-06 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法

Country Status (15)

Country Link
US (1) US9238030B2 (enExample)
EP (1) EP2773607B1 (enExample)
JP (1) JP6063472B2 (enExample)
KR (1) KR102336767B1 (enExample)
CN (1) CN103917514B (enExample)
AU (1) AU2012332111B2 (enExample)
BR (1) BR112014010584A2 (enExample)
CA (1) CA2853491C (enExample)
EA (1) EA027770B1 (enExample)
ES (1) ES2624427T3 (enExample)
IL (1) IL232452A (enExample)
MX (1) MX354653B (enExample)
SG (1) SG11201402056XA (enExample)
WO (1) WO2013067547A1 (enExample)
ZA (1) ZA201403003B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180072665A (ko) * 2015-07-28 2018-06-29 베타 캐트 파마슈티칼스, 인코포레이티드 안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
JP7159302B2 (ja) * 2017-06-02 2022-10-24 イテリオン・セラピューティクス・インコーポレイテッド 線維性疾患の治療のための方法
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581647A (en) * 2007-05-10 2012-02-24 Avalon Pharmaceuticals Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
WO2008147713A1 (en) 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
EA030302B1 (ru) * 2008-11-21 2018-07-31 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение
WO2011019648A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
EP2470534A4 (en) * 2009-08-24 2013-02-27 Merck Sharp & Dohme JAK INHIBITION FOR BLOCKING TOXICITY ASSOCIATED WITH RNA INTERFERENCE
CA2775155A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukemia

Also Published As

Publication number Publication date
EP2773607A1 (en) 2014-09-10
EP2773607A4 (en) 2015-03-11
NZ624446A (en) 2016-01-29
CA2853491A1 (en) 2013-05-10
SG11201402056XA (en) 2014-10-30
AU2012332111B2 (en) 2016-11-17
US20130143920A1 (en) 2013-06-06
WO2013067547A1 (en) 2013-05-10
EA201490937A1 (ru) 2014-08-29
AU2012332111A1 (en) 2014-05-22
ZA201403003B (en) 2017-08-30
HK1198440A1 (en) 2015-04-24
CN103917514A (zh) 2014-07-09
MX354653B (es) 2018-03-07
ES2624427T3 (es) 2017-07-14
JP2014534229A (ja) 2014-12-18
KR102336767B1 (ko) 2021-12-10
KR102336767B9 (ko) 2025-01-08
CN103917514B (zh) 2016-11-16
BR112014010584A2 (pt) 2017-05-02
US9238030B2 (en) 2016-01-19
MX2014005498A (es) 2016-05-05
EP2773607B1 (en) 2017-03-29
KR20140089418A (ko) 2014-07-14
CA2853491C (en) 2019-12-10
IL232452A (en) 2017-01-31
EA027770B1 (ru) 2017-08-31
IL232452A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
JP6342805B2 (ja) 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
JP6063472B2 (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
US20110046211A1 (en) Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
KR20130045341A (ko) 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
WO2014011284A1 (en) Method of treating gastrointestinal stromal tumors
KR20250099749A (ko) 약학적 조합물 및 이의 용도
KR20180064438A (ko) Ｎａｓｈ-연관 간암의 치료를 위한 ｅｐ4 수용체 길항제의 용도
KR20250069693A (ko) 암 치료
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
WO2019053595A1 (en) INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
CN107708700A (zh) 用于治疗癌症的方法
AU2020279003A1 (en) Oxathiazin compounds for inhibiting GAPDH
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
CN101674828A (zh) 用于治疗甲状腺癌的Raf抑制剂
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
JP2020083849A (ja) ガンを治療又は予防するための医薬組成物
NZ624446B2 (en) Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US9907797B2 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
Lu et al. Zandelisib. Phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, Treatment of B-cell lymphomas
TW202404609A (zh) 雜環次膦酸化合物之劑量及投藥方案
JP2023511072A (ja) 癌の治療のための組み合わせおよびその用途
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161216

R150 Certificate of patent or registration of utility model

Ref document number: 6063472

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250